

Andreas Pircher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6102905/publications.pdf>

Version: 2024-02-01

106
papers

4,410
citations

186265

28
h-index

118850

62
g-index

109
all docs

109
docs citations

109
times ranked

8157
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210819.	3.2	12
2	Hairy Cell Leukemia Patients Have a Normal Life Expectancyâ€”A 35-Year Single-Center Experience and Comparison with the General Population. <i>Cancers</i> , 2022, 14, 1242.	3.7	8
3	Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. <i>Molecular Cancer</i> , 2022, 21, .	19.2	32
4	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. <i>European Urology Oncology</i> , 2021, 4, 745-754.	5.4	17
5	Vaccination influenz(a)ing cancerâ€™specific survival. <i>International Journal of Cancer</i> , 2021, 148, 1806-1807.	5.1	0
6	High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 304-313.	2.8	23
7	Atezolizumab for PD-L1â€™Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2021, 384, 583-585.	27.0	4
8	Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 287-291.	0.5	1
9	High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4021-4021.	1.6	6
10	The Biology of Classic Hairy Cell Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7780.	4.1	8
11	Rare lung cancersâ€™Primary pulmonary leiomyosarcoma: Aâ€™case report. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 392-396.	0.5	1
12	Differential procoagulatory response of microvascular, arterial and venous endothelial cells upon inflammation in vitro. <i>Thrombosis Research</i> , 2021, 205, 70-80.	1.7	8
13	Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. <i>Lung Cancer</i> , 2021, 159, 84-95.	2.0	12
14	ASCO 2020 non-small lung cancer (NSCLC) personal highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 66-69.	0.5	27
15	ASCOâ€™2021â€™selection of personal highlights in early stage non-small cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 347.	0.5	2
16	Rare lung cancersâ€™2021 update on challenges, advances, and opportunities. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 317-318.	0.5	0
17	Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. <i>Cardiovascular Research</i> , 2020, 116, 970-982.	3.8	32
18	Cloak and dagger â€™secondary hemophyocytic lymphohistiocytosis caused by intravenous autoinfection. <i>American Journal of Hematology</i> , 2020, 95, 330-332.	4.1	1

#	ARTICLE	IF	CITATIONS
19	BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. <i>Leukemia</i> , 2020, 34, 1454-1457.	7.2	16
20	Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. <i>Current Opinion in Oncology</i> , 2020, 32, 44-53.	2.4	18
21	Creating the "new normal" post-Coronavirus world" web-communication replacing face-to-face interaction. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 245-246.	0.5	2
22	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 890-891.	27.0	9
23	Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment " New Findings and Future Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 766.	3.7	99
24	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. <i>Molecular Cancer</i> , 2020, 19, 141.	19.2	141
25	Young hematologists and medical oncologists in focus. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 9-10.	0.5	0
26	Evidence-based follow-up in lung cancer?. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 73-77.	0.5	8
27	Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102948.	4.4	21
28	An update from the 2019 ESMO meeting. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 139-140.	0.5	0
29	The Impact of Cand1 in Prostate Cancer. <i>Cancers</i> , 2020, 12, 428.	3.7	13
30	An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. <i>Cancer Cell</i> , 2020, 37, 21-36.e13.	16.8	253
31	ESMO 2019" personal non-small lung cancer highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 150-153.	0.5	1
32	Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological Angiogenesis. <i>Cell Metabolism</i> , 2020, 31, 862-877.e14.	16.2	169
33	The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer " New Combinational Approaches and Strategies of Neovessel Inhibition. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 610903.	3.7	24
34	Overcoming resistance and bypassing checkpoints" possible new therapeutic frontiers in oncology. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 105-106.	0.5	0
35	Saving lives with lung cancer screening. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 107-108.	0.5	0
36	Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature. <i>International Journal of Medical Sciences</i> , 2019, 16, 115-124.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 490.	2.8	85
38	ESMO 2018â€”personal highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 67-70.	0.5	0
39	Lowâ€”dose vemurafenib in hairy cell leukemia patients with active infection. <i>American Journal of Hematology</i> , 2019, 94, E180-E182.	4.1	27
40	Immunosuppression for Immune Checkpoint-related Toxicity Can Cause <i>Pneumocystis Jirovecii</i> Pneumonia (PJP) in Nonâ€”small-cell Lung Cancer (NSCLC): A Report of 2 Cases. <i>Clinical Lung Cancer</i> , 2019, 20, e247-e250.	2.6	24
41	EndoDB: a database of endothelial cell transcriptomics data. <i>Nucleic Acids Research</i> , 2019, 47, D736-D744.	14.5	70
42	Cytotoxics and Anti-angiogenics: Metronomic Therapies. , 2019, , 327-347.		0
43	Revival of anti-angiogenic therapies in cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 1-2.	0.5	0
44	Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. <i>Oncology Research and Treatment</i> , 2018, 41, 188-193.	1.2	35
45	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 293-305.	3.7	80
46	Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial. <i>Translational Andrology and Urology</i> , 2018, 7, S132-S134.	1.4	4
47	Cholesterol pathway the Achilles heel in prostate cancer metastasis. <i>Translational Andrology and Urology</i> , 2018, 7, S686-S687.	1.4	1
48	ASCO 2018 NSCLC highlightsâ€”combination therapy is key. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 266-271.	0.5	12
49	Antidiabetic drugs influence molecular mechanisms in prostate cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 1153-1161.	3.4	14
50	Phenotype molding of stromal cells in the lung tumor microenvironment. <i>Nature Medicine</i> , 2018, 24, 1277-1289.	30.7	1,126
51	Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells. <i>Cell Metabolism</i> , 2018, 28, 573-587.e13.	16.2	127
52	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. <i>PLoS ONE</i> , 2018, 13, e0202045.	2.5	40
53	Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1015-e1024.	1.9	12
54	Vessel pruning or healing: endothelial metabolism as a novel target?. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 239-247.	3.4	42

#	ARTICLE	IF	CITATIONS
55	ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer—results from an international multicenter study. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 271-275.	3.9	25
56	Tumor vessel disintegration by maximum tolerable PFKFB3 blockade. <i>Angiogenesis</i> , 2017, 20, 599-613.	7.2	73
57	Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. <i>Eur Urol</i> 2017;71:776–87. <i>European Urology</i> , 2017, 72, e102-e103.	1.9	1
58	Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2291.	4.1	40
59	Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 185-186.	0.5	3
60	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. <i>Oncotarget</i> , 2017, 8, 66849-66864.	1.8	47
61	Cytotoxics and Anti-Angiogenics: Metronomic Therapies. , 2017, , 1-22.		0
62	Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. <i>EMBO Molecular Medicine</i> , 2016, 8, 1134-1142.	6.9	83
63	Reply. <i>Clinical Lung Cancer</i> , 2016, 17, e187.	2.6	1
64	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. <i>Blood</i> , 2016, 127, 2847-2855.	1.4	100
65	Endothelial cell metabolism: A novel player in atherosclerosis? Basic principles and therapeutic opportunities. <i>Atherosclerosis</i> , 2016, 253, 247-257.	0.8	62
66	Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy. <i>Cancer Cell</i> , 2016, 30, 968-985.	16.8	464
67	Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis. <i>Clinical Lung Cancer</i> , 2016, 17, 62-67.e1.	2.6	18
68	Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies. <i>Oncotarget</i> , 2016, 7, 20109-20123.	1.8	14
69	Results of the REGATTA trial on surgical therapy of limited metastatic gastric cancer: open issues and future perspectives. <i>Translational Cancer Research</i> , 2016, 5, S178-S181.	1.0	0
70	High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance. <i>PLoS ONE</i> , 2015, 10, e0115537.	2.5	24
71	Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIa (INN06-Study). <i>PLoS ONE</i> , 2015, 10, e0125364.	2.5	6
72	NSCLC without Antineoplastic Treatment: Incidence, Characteristics, and Outcome as Outlined in the TYROL Study. <i>Oncology</i> , 2015, 89, 255-261.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Ulcerative skin metastases of primary lung cancer. Japanese Journal of Clinical Oncology, 2015, 45, 135-135.	1.3	0
74	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. Lung Cancer, 2015, 87, 193-200.	2.0	115
75	Treg(s) in Cancer: Friends or Foe?. Journal of Cellular Physiology, 2015, 230, 2598-2605.	4.1	105
76	Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study. Anticancer Research, 2015, 35, 5129-39.	1.1	3
77	Is there a role for angiogenesis inhibition in prostate cancer?. Memo - Magazine of European Medical Oncology, 2014, 7, 214-218.	0.5	1
78	New Antiangiogenic Strategies beyond Inhibition of Vascular Endothelial Growth Factor with Special Focus on Axon Guidance Molecules. Oncology, 2014, 86, 46-52.	1.9	18
79	Small steps of improvement in small-cell lung cancer (SCLC) within two decades: A comprehensive analysis of 484 patients. Lung Cancer, 2014, 84, 168-174.	2.0	27
80	Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemo-naïve patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). Lung Cancer, 2014, 85, 395-400.	2.0	13
81	Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 2014, 85, 81-87.	2.0	44
82	Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient. Lung Cancer, 2014, 83, 408-410.	2.0	5
83	BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib. Blood, 2014, 124, 3634-3634.	1.4	3
84	Polyarteritis nodosa complicating multiple myeloma " a case report and review of the literature. , 2014, 33, 143-157.		3
85	Paraneoplastic phenomena and diagnostic challenges in angioimmunoblastic T-cell lymphoma (AITL): report of two cases and review of the literature. In Vivo, 2014, 28, 327-32.	1.3	2
86	ASCO 2013: new developments in lung cancer. Memo - Magazine of European Medical Oncology, 2013, 6, 236-239.	0.5	0
87	Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs). Lung Cancer, 2013, 81, 252-258.	2.0	20
88	Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2013, 138, 248-256.	2.5	36
89	Docetaxel in the treatment of non-small cell lung cancer (NSCLC) – an observational study focusing on symptom improvement. Anticancer Research, 2013, 33, 3831-6.	1.1	10
90	Endothelial Progenitor Cells: Current Issues on Characterization and Challenging Clinical Applications. Stem Cell Reviews and Reports, 2012, 8, 926-939.	5.6	46

#	ARTICLE	IF	CITATIONS
91	Sorafenib in thyroid cancer—a retrospective case series. Memo - Magazine of European Medical Oncology, 2012, 5, 246-249.	0.5	0
92	Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation. BMJ Case Reports, 2012, 2012, bcr0220125856-bcr0220125856.	0.5	1
93	Targeting angiogenesis in lung cancer - Pitfalls in drug development. Translational Lung Cancer Research, 2012, 1, 122-8.	2.8	7
94	Cancer Stem Cells: Characteristics and Their Potential Role for New Therapeutic Strategies. Onkologie, 2011, 34, 269-274.	0.8	14
95	Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2011, 105, 72-80.	3.4	14
96	Molecular oncology in lung cancer — between biomarkers and clinical application. Relevance of the Ras—Raf—MEK—ERK pathway. Memo - Magazine of European Medical Oncology, 2011, 4, 242-247.	0.5	1
97	Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy. International Journal of Molecular Sciences, 2011, 12, 7077-7099.	4.1	66
98	Targeting the insulin-like growth factor network in cancer therapy. Cancer Biology and Therapy, 2011, 11, 701-707.	3.4	76
99	Liver cancer: Targeted future options. World Journal of Hepatology, 2011, 3, 38.	2.0	31
100	Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer. Anticancer Research, 2011, 31, 2949-55.	1.1	15
101	Biomarkers of angiogenesis and their role in clinical oncology. Memo - Magazine of European Medical Oncology, 2010, 3, 27-32.	0.5	2
102	Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer, 2010, 69, 265-271.	2.0	12
103	Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: A methodological challenge and an ongoing debate on the clinical relevance. Oncology Reports, 2008, , .	2.6	8
104	Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. Oncology Reports, 2008, 19, 345-52.	2.6	19
105	D6-04: Increased numbers of endothelial progenitor cells in peripheral blood and tumour specimens in non small cell lung cancer patients. A methodological challenge and ongoing debate on the clinical relevance. Journal of Thoracic Oncology, 2007, 2, S408.	1.1	0
106	Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities. Memo - Magazine of European Medical Oncology, 0, , .	0.5	0